These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 23942028)

  • 21. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists.
    Moreno JL; Holloway T; Albizu L; Sealfon SC; González-Maeso J
    Neurosci Lett; 2011 Apr; 493(3):76-9. PubMed ID: 21276828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration.
    Nichols CD; Garcia EE; Sanders-Bush E
    Brain Res Mol Brain Res; 2003 Mar; 111(1-2):182-8. PubMed ID: 12654518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Hallucinogens on Unconditioned Behavior.
    Halberstadt AL; Geyer MA
    Curr Top Behav Neurosci; 2018; 36():159-199. PubMed ID: 28224459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
    Meltzer HY; Huang M
    Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens.
    Titeler M; Lyon RA; Glennon RA
    Psychopharmacology (Berl); 1988; 94(2):213-6. PubMed ID: 3127847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development.
    Marek GJ
    Int Rev Neurobiol; 2007; 78():165-92. PubMed ID: 17349861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential serotonergic agents for the treatment of schizophrenia.
    Garay RP; Bourin M; de Paillette E; Samalin L; Hameg A; Llorca PM
    Expert Opin Investig Drugs; 2016; 25(2):159-70. PubMed ID: 26576669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An animal model of schizophrenia based on chronic LSD administration: old idea, new results.
    Marona-Lewicka D; Nichols CD; Nichols DE
    Neuropharmacology; 2011 Sep; 61(3):503-12. PubMed ID: 21352832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic infusion of PCP via osmotic mini-pumps: a new rodent model of cognitive deficit in schizophrenia characterized by impaired attentional set-shifting (ID/ED) performance.
    Pedersen CS; Goetghebeur P; Dias R
    J Neurosci Methods; 2009 Dec; 185(1):66-9. PubMed ID: 19761795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurotransmitter basis of the behavioral effects of hallucinogens.
    Rech RH; Commissaris RL
    Neurosci Biobehav Rev; 1982; 6(4):521-7. PubMed ID: 6817241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review.
    Reiche S; Hermle L; Gutwinski S; Jungaberle H; Gasser P; Majić T
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():1-10. PubMed ID: 28947181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors.
    Rodrigues da Silva N; Gomes FV; Sonego AB; Silva NRD; Guimarães FS
    Pharmacol Res; 2020 Jun; 156():104749. PubMed ID: 32151683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD).
    Brandt SD; Kavanagh PV; Westphal F; Stratford A; Elliott SP; Hoang K; Wallach J; Halberstadt AL
    Drug Test Anal; 2016 Sep; 8(9):891-902. PubMed ID: 26456305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT(2A) receptor.
    Halberstadt AL; Geyer MA
    Psychopharmacology (Berl); 2010 Feb; 208(2):179-89. PubMed ID: 19937319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topiramate antagonizes MK-801 in an animal model of schizophrenia.
    Deutsch SI; Rosse RB; Billingslea EN; Bellack AS; Mastropaolo J
    Eur J Pharmacol; 2002 Aug; 449(1-2):121-5. PubMed ID: 12163115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [SEROTONIN AND PSYCHIATRY].
    PELICIER Y
    Pathol Biol; 1964 Nov; 12():1107-9. PubMed ID: 14224288
    [No Abstract]   [Full Text] [Related]  

  • 37. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior.
    González-Maeso J; Weisstaub NV; Zhou M; Chan P; Ivic L; Ang R; Lira A; Bradley-Moore M; Ge Y; Zhou Q; Sealfon SC; Gingrich JA
    Neuron; 2007 Feb; 53(3):439-52. PubMed ID: 17270739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psilocybin as a discriminative stimulus: lack of specificity in an animal behavior model for 'hallucinogens'.
    Koerner J; Appel JB
    Psychopharmacology (Berl); 1982; 76(2):130-5. PubMed ID: 6805022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hallucinogenic drugs as precipitants of schizophrenia.
    Breakey WR; Goodell H; Lorenz PC; McHugh PR
    Psychol Med; 1974 Aug; 4(3):255-61. PubMed ID: 4427973
    [No Abstract]   [Full Text] [Related]  

  • 40. Hippocampal serotonin depletion facilitates the enhancement of prepulse inhibition by risperidone: possible role of 5-HT(2C) receptors in the dorsal hippocampus.
    Adams W; van den Buuse M
    Neuropharmacology; 2011 Sep; 61(3):458-67. PubMed ID: 21477601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.